FDA determines Afrezza REMS communication plan has met goals and REMS no longer necessary
MannKind announced the FDA has completed its review of a sNDA for Afrezza (insulin human) inhalation powder and has determined that the Risk Evaluation and Mitigation Strategy communication plan regarding the risks of Afrezza has been completed and has met its goals. April 25, 2018